← ANALYST RATINGS · TIPRANKS
Coya Therapeutics, Inc. (COYA): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $17.00, the highest $18.00, the lowest $16.00. The average is +300.0% from the last price of $4.25.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | −5.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $4.50+12.5% | Hold | +5.9% | Reiterated | 16.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $4.50+12.5% | Hold | +5.9% | Reiterated | 16.10.26on TipRanks 10:06 | — | |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $12.00 | Buy | +182.4% | Reiterated | 15.10.26on TipRanks 08:50 | +3.5%next day −1.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.00 → $4.50−10.0% | Hold | +5.9% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +5.9% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | −5.9% | Upgrade | 15.10.26on TipRanks 03:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $18.00 | Buy | +323.5% | Reiterated | 14.10.26on TipRanks 10:12 | −5.5%next day +3.5% | ↗ |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $17.00 | Buy | +300.0% | Reiterated | 06.10.26on TipRanks 08:50 | −0.5%next day +1.5% · 5 days −7.6% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $16.00 | Buy | +276.5% | Reiterated | 11.08.26on TipRanks Aug 12 07:30 | +3.8%next day −2.5% · 5 days +2.9% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $14.00 | Buy | +229.4% | Reiterated | 12.05.26on TipRanks 23:30 | +5.3%next day +15.1% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Coya Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $15.75 at a price of $4.85 (+224.7%); now: $15.75 at $4.25 (+270.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.34 (from $-0.37 to $-0.27). Last quarter: $-0.28.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Coya Therapeutics, Inc.
- CEO: Arun Swaminathan
- Employees: 8
- 5850 San Felipe Street, Houston, TX, 77057, US
- www.coyatherapeutics.com
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Data from the stock’s TipRanks forecast page, read 98 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗